Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II temozolomide plus fotemustine in recurrent glioblastoma
2008-001645-26Phase 2Terminated
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Jun 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and fotemustine in glioblastoma (GBM), sponsored by Carlo Besta Neurological Institute. Primary endpoint: Progression-free survival at 6 months. Started Jun 2008; status: terminated.
02
Drugs
temozolomidefotemustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-001645-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001645-26.